Dennis Cho Sells 6,515 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 6,515 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $204,831.60. Following the transaction, the insider owned 121,713 shares in the company, valued at $3,826,656.72. The trade was a 5.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total transaction of $124,768.44.
• On Monday, September 22nd, Dennis Cho sold 233 shares of Twist Bioscience stock. The shares were sold at an average price of $27.56, for a total transaction of $6,421.48.
• On Monday, September 15th, Dennis Cho sold 94 shares of Twist Bioscience stock. The shares were sold at an average price of $25.33, for a total transaction of $2,381.02.
• On Monday, September 8th, Dennis Cho sold 269 shares of Twist Bioscience stock. The shares were sold at an average price of $25.76, for a total transaction of $6,929.44.

Twist Bioscience Price Performance

TWST traded down $1.32 during midday trading on Monday, hitting $31.57. 1,224,978 shares of the company traded hands, compared to its average volume of 1,305,728. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -21.77 and a beta of 2.38. Twist Bioscience Corporation has a 52-week low of $24.07 and a 52-week high of $55.33. The business has a 50 day simple moving average of $28.97 and a two-hundred day simple moving average of $31.82.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. On average, equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TWST shares. Evercore ISI decreased their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Barclays decreased their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Finally, Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.56.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock worth $95,883,000 after purchasing an additional 1,588,587 shares in the last quarter. Strs Ohio acquired a new stake in Twist Bioscience during the first quarter worth approximately $711,000. GAMMA Investing LLC increased its holdings in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after acquiring an additional 303 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $396,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $228,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.